CITF Research Results

CITF Research Results2021-10-12T16:15:35-04:00

Researchers identify features associated with heightened risk of myocarditis/pericarditis following mRNA vaccination

A team that included CITF-funded researcher Dr. Jeffrey Kwong from ICES and Public Health Ontario has found that 70% of cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the sac holding the heart) following COVID-19 vaccination in Ontario occurred after the second dose. From December 14, 2020, to September 4, 2021, during which 19.7 million doses of mRNA vaccine were [...]

December 13, 2021|General vaccine surveillance|

Immune cell analysis reveals the amount of SARS-CoV-2 in blood is a strong predictor of mortality

CITF-funded researchers Drs. Daniel Kaufmann, Andrés Finzi and Nicolas Chomont from the Université de Montréal and the Université de Montréal hospital research centre (CRCHUM), along with their collaborators, found that the amount of viral mRNA  in the blood can help identify hospitalized patients who will suffer severe COVID-19, and even death. The discovery of molecular markers to help identify individuals at risk of severe [...]

December 13, 2021|Immune science|

Previous infection with common cold seasonal coronavirus may help protect against COVID-19

Nearly everyone has been exposed to the highly prevalent seasonal coronaviruses responsible for the common cold. But could this exposure induce antibodies that also recognize certain proteins of the SARS-CoV-2 virus? A study led by University of Ottawa researcher Dr. Marc-André Langlois, now published in EBio Medicine, proposes that some individuals previously infected with certain seasonal coronaviruses may have pre-existing protective immune responses against [...]

December 6, 2021|Immune science|

Increased dosing intervals leads to increased antibody levels and neutralization

Extending the interval between COVID-19 vaccine doses was introduced in Canada to accelerate population coverage with a single dose. In research published in JAMA, Drs. Brian Grunau, David Goldfarb, and Pascal Lavoie from the University of British Columbia studied the vaccine-induced antibody levels in paramedics enrolled in a CITF-funded study who were immunized with mRNA vaccines at differing dosing intervals. They show that longer [...]

December 6, 2021|Healthcare workers|

Antibody wane being observed yet breakthrough infections rare: Latest Canadian Blood Services report

In their latest report, Canadian Blood Services reveals that 97% of blood donors sampled in September had evidence of antibodies against SARS-CoV-2 acquired through immunization with at least one vaccine dose and/or a past infection. This number is largely driven by vaccination as infection-acquired seroprevalence remained low in September - at 4.4% - despite the ongoing fourth wave. September results show evidence of antibody [...]

December 6, 2021|General population studies|

Delaying second dose of mRNA COVID-19 vaccine produces stronger immune response

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF). Principal investigator Dr. Brian Grunau, Assistant Professor in UBC’s Department of Emergency Medicine and Scientist at [...]

December 1, 2021|Healthcare workers, Media Releases|

How adolescents with inflammatory bowel disease treated with immunosuppressive drugs respond to COVID-19 vaccination

In a letter published in Gut, Dr. Kevan Jacobson, Dr. Pascal Lavoie and collaborators from the University of British Columbia report modestly lower antibody levels in adolescents, aged 12 to 17 years, with inflammatory bowel disease (IBD) who are on the anti-TNF-a anti-inflammatory therapy infliximab in combination with other immunosuppressive drugs or given as monotherapy, after a first dose of Pfizer-BioNTech’s Comirnaty vaccine. However, [...]

November 30, 2021|Pediatrics|

Making life easier for researchers doing systematic reviews of seroprevalence studies

Making life easier for researchers doing systematic reviews of seroprevalence studies Researchers at CITF-funded Serotracker present a new automated tool designed for risk of bias assessment (ROB). Because ROB can be a time consuming and subjective task when performing a systematic review, in this preprint, not yet peer reviewed, the authors offer a set of rules for transparent and reproducible assessments of seroprevalence studies. [...]

November 30, 2021|Other|

Low transmission of SARS-CoV-2 observed in kindergarten to grade 12 schools in British Columbia

Drs. Pascal Lavoie and Louise Mâsse from the University of British Columbia and their team have released new findings from their CITF-funded study of SARS-CoV-2 transmission in Vancouver schools. In a pre-print, not-yet peer reviewed, their results suggest that despite the presence of variants of concern last spring, there was low transmission of SARS-CoV-2 in schools from kindergarten to grade 12, where appropriate disease [...]

November 30, 2021|Pediatrics|
Go to Top